BioSpace News Archive

VBI Vaccines Inc. today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 21-24.

Nascent Biotech, Inc. presented their Phase I Clinical Data at the American Society of Clinical Oncology (ASCO) meeting in Chicago in a poster presentation.

Structure Therapeutics Inc. today announced that clinical and preclinical data from its oral GLP-1 receptor agonist GSBR-1290 program will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions taking place June 23-26, 2023, in San Diego.

Alpha Cognition Inc. is pleased to announce the that it has been awarded a $750,000 grant from the Army Medical Research and Material Command (AMRMC) for a pre-clinical study on the use of ALPHA-1062 Intranasal (IN) to reduce blast mTBI induced functional deficit and brain abnormalities.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Bill Little as EVP of Corporate Development and Strategy and Andrew Taylor as CFO.

Trinity Life Sciences announced today the appointment of Leslie Orne as Chief Executive Officer (CEO) effective July 1.

MEKanistic Therapeutics Inc. announces the addition of Dr. Patricia LoRusso to its Scientific Advisory Board.

TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Dr. K. Arnold Chan joined the company as Senior Vice President, Real-World Evidence Consulting.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced that as of June 2, 2023, it entered into a new $750,000 term loan with Main Street Bank.

Vaxart, Inc. announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Vaxart.